Primary Mitochondrial Myopathy (PMM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Primary Mitochondrial Myopathies (PMMs) are disorders that cause oxidative phosphorylation (OXPHOS) abnormalities that primarily, but not exclusively, damage skeletal muscle. Progressive external ophthalmoplegia (PEO), eyelid ptosis, exercise intolerance, and muscle weakness are the most common symptoms of myopathy that occur in mitochondrial diseases. It is a genetically defined disorder leading to defects of oxidative phosphorylation affecting predominantly, but not exclusively, lean muscle. The indications and symptoms of PMM vary, and how one of these disorders affects one individual may differ significantly from how it affects another. This is true for persons with the same condition or even people from the same family with the same genetic variant. A gene mutation causes primary mitochondrial myopathies. When a gene variant arises, the protein product may be defective, inefficient, nonexistent, or overproduced. This can affect numerous body organ systems, including the brain, depending on the functions of the specific protein. Most genes linked to primary mitochondrial myopathy encode proteins required for mitochondrial operation, development, and health.

 

 

The competitive landscape of Primary Mitochondrial Myopathy (PMM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Primary Mitochondrial Myopathy (PMM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Primary Mitochondrial Myopathy (PMM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Primary Mitochondrial Myopathy (PMM) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Elamipretide      Stealth BioTherapeutics Inc.      Phase 3

2          Omaveloxolone capsules           Reata Pharmaceuticals, Inc.            Phase 2

3          Bocidelpar         Astellas Pharma Inc      Phase 3

4          REN001            Reneo Pharma Ltd        Phase 3

5          KH176  Khondrion BV    Phase 2

6          IW-6463 Tablets            Cyclerion Therapeutics  Phase 2

7          Idebenone        Santhera Pharmaceuticals         Phase 2

8          MT1621            Modis Therapeutics, Inc.            Phase 3

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more